An Open Label, Phase I Trial of Intravenous Once Every 2 Weeks Administration of BI 6727 (Volasertib) in Japanese Patients With Acute Myeloid Leukemia.

Trial Profile

An Open Label, Phase I Trial of Intravenous Once Every 2 Weeks Administration of BI 6727 (Volasertib) in Japanese Patients With Acute Myeloid Leukemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Volasertib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim; Nippon Boehringer Ingelheim
  • Most Recent Events

    • 19 Jun 2017 Data from this and other two trials NCT00804856 and NCT01721876 was used to develop a population model characterising the pharmacokinetic profiles of volasertib and cytarabine were published in the Clinical Pharmacokinetics.
    • 30 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 09 Feb 2015 Planned end date changed from 1 Feb 2015 to 1 Sep 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top